Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
- Conditions
- Interventions
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 862
- Registration Number
- NCT00091819
- Locations
- 🇺🇸
Paradise Valley Hospital, 2400 E. 4th Street, National City, California, United States
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 859
- Registration Number
- NCT00003805
- Locations
- 🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇨🇭Universitaetsspital, Zurich, Switzerland
🇨🇭Ospedale San Giovanni, Bellinzona, Switzerland
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1077
- Registration Number
- NCT00087490
- Locations
- 🇻🇪
Pfizer Investigational Site, Valencia, Venezuela
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1225
- Registration Number
- NCT00084266
- Locations
Pfizer Investigational Site
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
- Conditions
- First Posted Date
- 2002-05-15
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 739
- Registration Number
- NCT00037050
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00035425
- Locations
Pfizer Investigational Site
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.